Pediatrics & Neonatology
Volume 49, Issue 5 , Pages 161-165, October 2008

Intravenous Pamidronate Therapy in Taiwanese Patients with Osteogenesis Imperfecta

  • Hsiang-Yu Lin

      Affiliations

    • Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    • Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
    • Mackay Medicine, Nursing and Management College, Taipei, Taiwan
    • Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Shuan-Pei Lin

      Affiliations

    • Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    • Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
    • Mackay Medicine, Nursing and Management College, Taipei, Taiwan
    • Department of Infant and Child Care, National Taipei College of Nursing, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Pediatrics, Mackay Memorial Hospital, 92 Section 2, Chung-Shan North Road, Taipei 10449, Taiwan
    • ,
  • Chih-Kuang Chuang

      Affiliations

    • Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
    • Medical College, Fu-Jen Catholic University, Taipei, Taiwan
    • ,
  • Ming-Ren Chen

      Affiliations

    • Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    • Mackay Medicine, Nursing and Management College, Taipei, Taiwan
    • ,
  • Chia-Ying Chang

      Affiliations

    • Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan

Received 14 February 2008; received in revised form 16 July 2008; accepted 19 September 2008.

Article Outline

Background

Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our experience using pamidronate in Taiwanese patients with OI.

Methods

Twenty-six patients with type I, III, or IV OI (eight males and 18 females; age range at last follow-up, 2.9-39.2 years) who received (or were currently receiving) intravenous pamidronate treatment (30 mg/m2/dose, every month) were retrospectively analyzed. Patients were followed for 1.0-7.3 years over the study period from February 2000 to October 2007.

Results

The mean standard deviation score (SDS) for bone mineral density (BMD) had increased significantly from −4.72 to −3.37 (p < 0.005) after 1 year of treatment. In 16 patients evaluated after 4 years and eight after 6 years, the mean SDS continued to improve, to −2.69 (p < 0.001) and −1.54 (p < 0.005), respectively. The fracture rate decreased significantly (from 2.8 ± 1.1 to 0.6 ± 0.6, p < 0.001), and nine patients (35%) had no fractures while receiving treatment. The response to pamidronate was significantly better in patients with poorer initial BMD SDS (1 year: r = −0.71, p < 0.01; 4 years: r = −0.81, p < 0.01).

Conclusion

This retrospective study suggests that Taiwanese patients with OI can benefit from pamidronate treatment, leading to a reduced incidence of fractures and increased BMD, especially in patients with poor baseline BMD.

Key Words:  bisphosphonates , bone mineral density , fracture , osteogenesis imperfecta , pamidronate

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Smith R . Osteogenesis imperfecta: from phenotype to genotype and back again . Int J Exp Pathol . 1994;75:233–241
  2. Sykes B , Ogilvie D , Wordsworth P , et al.   Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2 . Am J Hum Genet . 1990;46:293–307
  3. Sillence DO , Senn A , Danks DM . Genetic heterogeneity in osteogenesis imperfecta . J Med Genet . 1979;16:101–116
  4. Rauch F , Glorieux FH . Osteogenesis imperfecta . Lancet . 2004;363:1377–1385
  5. Aström E , Jorulf H , Söderhäll S . Intravenous pamidronate treatment to infants with severe osteogenesis imperfecta . Arch Dis Child . 2007;92:332–338
  6. Åström E , Söderhäll S . Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta . Acta Paediatr . 1998;87:64–68
  7. Åström E , Söderhäll S . Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta . Arch Dis Child . 2002;86:356–364
  8. Bajpai A , Kabra M , Gupta N , Sharda S , Ghosh M . Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome . J Pediatr Orthop . 2007;27:225–227
  9. DiMeglio LA , Ford L , McClintock C , et al.   Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta . Bone . 2004;35:1038–1045
  10. Forin V , Arabi A , Giugonis V , et al.   Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study . Joint Bone Spine . 2005;72:313–318
  11. Glorieux FH , Bishop NJ , Plotkin H , Chabot G , Lanoue G , Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta . N Engl J Med . 1998;339:947–952
  12. Antoniazzi F , Zamboni G , Lauriola S , Donadi L , Adami S , Tatò L . Early bisphosphonate treatment in infants with severe osteogenesis imperfecta . J Pediatr . 2006;149:174–179
  13. Löwing K , Aström E , Oscarsson KA , et al.   Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta . Acta Paediatr . 2007;96:1180–1183
  14. Plotkin H , Rauch F , Bishop NJ , et al.   Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age . J Clin Endocr Metab . 2000;85:1846–1850
  15. Zacharin M , Kanumakala S . Pamidronate treatment of less severe forms of osteogenesis imperfecta in children . J Pediatr Endocrinol Metab . 2004;17:1511–1517
  16. Rauch F , Plotkin H , Zeitlin L , et al.   Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy . J Bone Miner Res . 2003;18:610–614
  17. Zacharin M , Bateman J . Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response . J Pediatr Endocrinol Metab . 2002;15:163–174
  18. Zeitlin L , Rauch F , Plotkin H , et al.   Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Types I, III and IV . Pediatrics . 2003;111:1030–1036
  19. Falk MJ , Heeger S , Lynch KA , et al.   Intravenous bisphosphonate therapy in children with osteogenesis imperfecta . Pediatrics . 2003;111:573–578
  20. Choi JH , Shin YL , Yoo HW . Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta . J Korean Med Sci . 2007;22:209–212
  21. Lee YS , Low SL , Lim LA , Loke KY . Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta . Eur J Pediatr . 2001;160:641–644
  22. Chen W , Tsai CY , Chen AC , et al.   Growth charts of Taiwanese youth: norms based on health-related physical fitness . Mid Taiwan J Med . 2003;8(Suppl 2):S85–S93
  23. Bachrach LK , Hastie T , Wang MC , Narasimhan B , Marcus R . Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study . J Clin Endocrinol Metab . 1999;84:4702–4712
  24. van der Sluis IM , de Ridder MA , Boot AM , Krenning EP , de Muinck Keizer-Schrama SM . Reference data for bone density and body composition measured with dual energy x-ray absorptiometry in white children and young adults . Arch Dis Child . 2002;87:341–347
  25. Whyte MP , Wenkert D , Clements KL , McAlister WH , Mumm S . Bisphosphonate-induced osteopetrosis . N Engl J Med . 2003;349:457–463
  26. Marini JC . Do bisphosphonates make children's bones better or brittle? . N Engl J Med . 2003;349:423–426
  27. Janssen van Doorn K , Neyns B , Van der Niepen P , Verbeelen D . Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases . Nephron . 2001;89:467–468

PII: S1875-9572(09)60002-4

doi:10.1016/S1875-9572(09)60002-4

Pediatrics & Neonatology
Volume 49, Issue 5 , Pages 161-165, October 2008

Article Tools